2269:HKG
WuXi Biologics (Cayman) Inc
HK$32.74
arrow_upward
+0.99%(+0.32) 1D
Jun 5, 4:09:10 PM GMT+8 · HKD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2269...
Open
HK$33.04
High
HK$33.86
Low
HK$32.52
Mkt. cap
133.44B
Avg. vol.
27.51M
Volume
24.57M
P/E ratio
24.03
52-wk high
HK$44.00
52-wk low
HK$23.10
EPS
HK$1.36
Shares outstanding
1.23B
No. of employees
13K
Open
HK$33.04
High
HK$33.86
Low
HK$32.52
Mkt. cap
133.44B
Avg. vol.
27.51M
Volume
24.57M
P/E ratio
24.03
52-wk high
HK$44.00
52-wk low
HK$23.10
EPS
HK$1.36
Shares outstanding
1.23B
No. of employees
13K
Analyst outlook
Analyst Ratings
Based on 12 analysts giving stock ratings to 2269 in the past 3 months
Strong Buy
Buy
11
Hold
1
Sell
0
12 month forecast
Based on 12 Wall Street analysts offering 12 month price targets for 2269 in the last 3 months.
Highest
Current HK$32.74
HK$54.49 (+66.43%)
Average
HK$45.35 (+38.53%)
Lowest
HK$37.00 (+13.01%)
News stories
From sources across the web
Simply Wall Street
·
8 hours ago
Is WuXi Biologics (SEHK:2269) Offering Value After Its Recent Share Price Recovery?
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About WuXi Biologics (Cayman) Inc
AI content may include mistakes. Learn more